SCYNEXIS Inc. | Balance Sheet

Fiscal year is January-December. All values USD Thousands.
2013
2014
2015
2016
2017
2018
Cash & Short Term Investments
1,454.00
32,243.00
46,985.00
58,586.00
43,893.00
44,212
Total Accounts Receivable
1,062.00
1,727.00
930.00
233.00
251.00
6,732
Other Current Assets
2,264.00
766.00
522.00
508.00
816.00
519
Total Current Assets
4,780.00
34,736.00
48,437.00
59,327.00
44,960.00
51,463
Net Property, Plant & Equipment
5,401.00
4,835.00
-
-
-
516
Other Assets
2,258.00
101.00
836.00
465.00
890.00
918
Total Assets
12,439.00
39,672.00
49,273.00
59,792.00
45,850.00
53,170
ST Debt & Current Portion LT Debt
15,000.00
-
-
-
4,349.00
Accounts Payable
1,932.00
855.00
619.00
2,192.00
3,833.00
Other Current Liabilities
1,545.00
2,946.00
6,045.00
1,525.00
1,962.00
Total Current Liabilities
18,477.00
3,801.00
6,664.00
3,717.00
10,144.00
Long-Term Debt
-
-
-
14,252.00
10,303.00
Other Liabilities
2,662.00
2,440.00
660.00
7,004.00
3,993.00
Total Liabilities
21,139.00
6,241.00
7,324.00
24,973.00
24,440.00
Common Equity (Total)
8,700.00
33,431.00
41,949.00
34,819.00
21,410.00
Total Shareholders' Equity
8,700.00
33,431.00
41,949.00
34,819.00
21,410.00
Total Equity
8,700.00
33,431.00
41,949.00
34,819.00
21,410.00
Liabilities & Shareholders' Equity
12,439.00
39,672.00
49,273.00
59,792.00
45,850.00

About SCYNEXIS

View Profile
Address
1 Evertrust Plaza
Jersey City New Jersey 07302
United States
Employees -
Website http://www.scynexis.com
Updated 07/08/2019
SCYNEXIS, Inc. engages in the development and commercialization of novel anti-infectives, which addresses the significant unmet therapeutic needs. It develops a novel oral and intravenous drug for several fungal infections, including serious and life-threatening invasive fungal infections. The company was founded by Scot Kevin Huber, Terry Eugene Marquardt, Pierre Bernard Jacques Monnet, Russell J.